According to Bio-Rad Laboratories's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -53.3077. At the end of 2022 the company had a P/E ratio of -3.47.
Year | P/E ratio | Change |
---|---|---|
2022 | -3.47 | -165.53% |
2021 | 5.30 | 16.25% |
2020 | 4.56 | -27.43% |
2019 | 6.28 | -67.07% |
2018 | 19.1 | -70.6% |
2017 | 64.9 | -65.84% |
2016 | 190 | 429.94% |
2015 | 35.8 | -8.46% |
2014 | 39.1 | -13.87% |
2013 | 45.4 | 159.13% |
2012 | 17.5 | 16.5% |
2011 | 15.1 | -2.88% |
2010 | 15.5 | -15.16% |
2009 | 18.3 | -19.95% |
2008 | 22.8 | -23.36% |
2007 | 29.8 | 41.45% |
2006 | 21.1 | 0.69% |
2005 | 20.9 | -3.43% |
2004 | 21.6 | 12.62% |
2003 | 19.2 | 34.12% |
2002 | 14.3 | -18.94% |
2001 | 17.7 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 11.0 | -120.60% | ๐บ๐ธ USA |
![]() Thermo Fisher Scientific TMO | 32.3 | -160.63% | ๐บ๐ธ USA |
![]() Agilent Technologies A | 33.4 | -162.60% | ๐บ๐ธ USA |
![]() Becton Dickinson BDX | 42.6 | -179.83% | ๐บ๐ธ USA |
![]() General Electric GE | 14.2 | -126.72% | ๐บ๐ธ USA |
![]() Danaher DHR | 27.8 | -152.23% | ๐บ๐ธ USA |
![]() PerkinElmer
PKI | 15.0 | -128.08% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.